Wyeth Research

In 1999, CAT and Wyeth (http://www.wyeth.com), formerly the research division of Wyeth-Ayerst Laboratories) entered into a three-part agreement; a research collaboration, a product collaboration and a library licence option.

Under the terms of the research collaboration, Wyeth funded CAT to generate and isolate antibodies against Wyeth's targets. Wyeth has the option to develop human monoclonal antibody drug candidates derived from the collaboration and CAT will receive milestone payments during the course of development and royalty payments in respect of sales of these products. Wyeth has subsequently taken two exclusive product licences to human monoclonal antibodies identified through the research carried out at CAT, including MYO-029, which is being developed as a potential treatment for muscle-wasting disease.

Under the product collaboration, Wyeth and CAT isolated and developed antibodies to validate proprietary targets, with the goal of generating human monoclonal antibody therapeutics. Each company was given the opportunity to select antibody drug candidates for further development from this portfolio and each party paid its own product validation costs. For any products developed by Wyeth, CAT will receive licence fees, milestone payments during the course of development and royalty payments on sales. For any products developed by CAT, Wyeth will receive licence fees, milestone and royalty payments.

In 2004, Wyeth exercised their option to license CAT's antibody libraries for in-house use across a broad range of therapeutic areas, with on-going expert support from the technology transfer team and product development options.